Ataluren API Manufacturers

compare suppliers & get competitive offers



Selected filters:

Production region




To view suppliers for this material, you need to be logged in first.






This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.



Looking for Ataluren API 775304-57-9?

Here you will find a list of producers, manufacturers and distributors of Ataluren. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Cas Number:
DrugBank number:
Unique Ingredient Identifier:

About Ataluren

Why are people looking for Ataluren? Ataluren is a novel, orally administered drug that targets nonsense mutations. Ataluren is approved for use by the European Medicines Agency to treat Duchenne Muscular Dystrophy in patients aged 5 years and older who are able to walk. More specifically, ataluren is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation’) in the dystrophin gene. This drug does not yet have approval by the US Food and Drug Administration or by Health Canada for any indications.

You can ask the supplier about all relevant certificates for the product such as CoA, Safety Data Sheet and DMF.

Ataluren is a type of Means for diseases of the bone and muscular system

The pharmaceutical API subcategory known as "Means for diseases of the bone and muscular system" refers to a specialized class of active pharmaceutical ingredients (APIs) designed to target and treat various disorders related to the skeletal and muscular systems. These APIs play a crucial role in the development of medications that alleviate symptoms and improve the quality of life for individuals affected by bone and muscular conditions.

One common group of APIs in this subcategory includes bisphosphonates, which are widely used for the treatment of osteoporosis. These compounds inhibit bone resorption, thereby increasing bone density and reducing the risk of fractures. Bisphosphonates act by targeting specific enzymes involved in bone breakdown, preventing excessive bone loss.

Another significant class of APIs for bone and muscular diseases are muscle relaxants. These compounds help alleviate muscle spasms and stiffness associated with conditions such as muscle strains, sprains, and certain neurological disorders. Muscle relaxants work by interfering with the signals sent between the brain and the muscles, inducing relaxation and reducing pain.

Additionally, APIs like calcitonin analogs are utilized for the management of conditions such as Paget's disease and osteoporosis. Calcitonin analogs function by inhibiting osteoclast activity, reducing bone resorption, and promoting bone formation.

In summary, the subcategory of "Means for diseases of the bone and muscular system" encompasses APIs that target bone metabolism, muscle relaxation, and bone remodeling processes. These pharmaceutical ingredients play a vital role in the development of medications aimed at improving the well-being and mobility of individuals suffering from bone and muscular disorders.

Ataluren (Means for diseases of the bone and muscular system), classified under Metabolic Bone Disease Agents

Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.

The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.

These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.

Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.

In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.